Theravance Biopharma. has been granted a patent for compounds that inhibit neprilysin, along with related pharmaceutical compositions and methods for their use. The patent includes claims for treating diseases associated with neprilysin through the administration of these compounds. GlobalData’s report on Theravance Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Theravance Biopharma, was a key innovation area identified from patents. Theravance Biopharma's grant share as of July 2024 was 64%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12016835B2 outlines a method for treating diseases that are mediated by neprilysin, targeting subjects in need of such treatment. The method involves administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and an effective amount of a specific compound, referred to as formula (Ma). The diseases addressed by this method include cardiovascular diseases such as hypertension and heart failure, as well as renal diseases, diarrhea, glaucoma, and pain. The claims also specify the potential for combining this treatment with various therapeutic agents, including adenosine receptor antagonists, angiotensin-converting enzyme inhibitors, and other classes of medications that may enhance the treatment's efficacy.
Further claims detail the inclusion of specific types of AT1 receptor antagonists, listing numerous compounds such as losartan and valsartan, which can be used in conjunction with the primary treatment. The patent also provides specific structural details regarding the compound of formula (Ma), including variations in substituents (R1, R2, R3, and R4) and their respective chemical groups. This comprehensive approach allows for a tailored treatment strategy that can address multiple conditions associated with neprilysin, potentially improving patient outcomes through a combination of targeted therapies.
To know more about GlobalData’s detailed insights on Theravance Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
